Agoracom Blog Home

Posts Tagged ‘CSE’

« Older Entries
Newer Entries »

AGORACOM Welcomes TransCanna $TCAN.ca Developing The largest Multi-Purpose #Cannabis Facility in California, $2M In April Revenues and $24.6M Run Rate From Test Facility $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 2:23 PM on Friday, May 29th, 2020
TransCanna (@TransCanna) | Twitter

(CSE: TCAN) (FSE: TH8)

Why TransCanna?

  • $2M CAD Revenue April 2020
  • $24.6M CAD Revenue Run Rate solely from TransCanna test facility
  • $90M Annual Revenue expected from first full year upon completion of 196,000 Sq Ft Daly facility Q3 2021
  • Daly facility will be one of the largest cannabis facilities in California
  • Recently acquired two California companies,
    • High-end award winning edible producer Soldaze
    • Premium indoor cultivator and distributer Lyfted Farms
  • Lyfted Farms products sold in select Cookies Locations – The most recognizable name in high-end Cannabis.
  • 2019 California Cannabis sales over $3B, industry currently fragmented
  • Direct to dispensary model, cutting out the middleman

THE FACILITY – 196,000 Sq Ft DALY BUILDING

  • Located in Modesto, California; A key asset for TransCanna
  • 196,000 square foot building has an appraised value, prior to licensing and build out, of US $15m.
  • The indicative value once operational, post-licensing and build out is projected at US $80m.
  • Will be the largest multi-purpose cannabis facility in California.
  • Electricity Rates amongst the lowest in California

Daly building will serve as TransCanna’s operations headquarters and will house manufacturing, distribution and cultivation space.

A breakdown of the 196,000 square feet upon completion will be:

  • 45,000 square feet of manufacturing
  • 50,000 square feet of distribution, packaging and cannabis storage
  • 60,000 square feet of indoor cultivation space
  • 5,000 square feet of independent lab for product testing
  • 36,000 square feet of offices, equipment maintenance, employee areas
https://youtu.be/CbZz_yZQ4nE

Tags: , , , , ,
Posted in AGORACOM Clients (New), All Recent Posts, Featured, TransCanna Holdings Inc. | Comments Off on AGORACOM Welcomes TransCanna $TCAN.ca Developing The largest Multi-Purpose #Cannabis Facility in California, $2M In April Revenues and $24.6M Run Rate From Test Facility $CGC $ACB $APH $CRON.ca $OGI.ca

VIDEO: Aurora Cannabis $ACB Founder, Terry Booth, Is Taking Eyecarrot Vision Therapy Global $EYC.ca / $EYCCF

Posted by AGORACOM-JC at 6:15 PM on Thursday, May 28th, 2020
http://www.smallcapepicenter.com/eyc%20square.png

Eyecarrot Innovations (EYC:TSXV) is a Vision Therapy and Training Company that goes well beyond fixing eyes that simply can’t read letters on an eye chart. That’s what your optometrist does when they prescribe glasses.

What Eyecarrot does is far more exciting and groundbreaking. Without getting scientific, Eyecarrot delivers higher performing brains by optimizing the performance of your eyes.  The result is a faster brain through stronger eyes, which creates quite the edge for the world’s best athletes and explains why their client list includes:

  • Dallas Stars (NHL)
  • Chicago Cubs (MLB)
  • Sporting KC (MLS)
  • Tennis Canada
  • Showcased During NFL Scouting Combine
  • Eli Wilson Goaltending – The World Leader In Hockey Goaltending Development

BUT NEW EXECUTIVE CHAIRMAN, TERRY BOOTH, HAS A DIFFERENT AND BIGGER VISION (PARDON THE PUN) FOR EYECARROT – GLOBAL CHILDREN  

When Terry’s daughter was 1 years old, she developed eye problems that could only be treated by patching -  something he says would be considered “barbaric” today.  Terry discovered that 1 in 4 kids (not a typo) have vision problems beyond those treatable by an optometrist.  This was a global, epidemic without a solution that often leads to kids losing critical learning time and self-confidence by Grade 3.    

Fast Forward 30 years to about 4 weeks ago and Terry finally found the solution – Eyecarrot – but not before he and his science team put CEO Adam Cegielski and the Company through the ringer.  When the due diligence was complete, Terry Booth was all in….  

… And he’s bringing his entire science, government and finance network to the table to bring Eyecarrot to children around the world.    

Turn off NetFlix. Ignore your social media notifications.  Grab your favourite beverage, call a couple of friends and watch this interview … twice.  

Can’t spare enough time to stare at a screen?

Take AGORACOM with you in your car or on your walk by Podcast on Apple, Google, Spotify or your favourite podcaster.

Tags: , , ,
Posted in AGORACOM Via Satellite, All Recent Posts, Eyecarrot Innovations Corp, Featured | Comments Off on VIDEO: Aurora Cannabis $ACB Founder, Terry Booth, Is Taking Eyecarrot Vision Therapy Global $EYC.ca / $EYCCF

CLIENT FEATURE: Else Nutrition $BABY.ca The Award Winning, Plant-Based Nutrition Company For Small Cap Investors $MAT $KMB $BMY $ABT $WYE

Posted by AGORACOM-JC at 3:53 PM on Thursday, May 28th, 2020
http://blog.agoracom.com/wp-content/uploads/2020/03/else-square-150x150.png

Highlights

  • $CAD 10 million cash and runway for well over a year;
  • Backed By A Billion Dollar Global Nutrition Company;
  • MOU For International Distribution Of Products
  • US Product Launch Planned For Q3-2020;
  • “Best Health” Award At Global Food Innovation Summit In Milan;
  • Awarded Patents In 22 Countries, 44 Countries Pending;
  • Executives & Advisors From Globally Renowned Companies & Institutions

Here’s What The Experts Say

“Finally a high quality, nutritionally-dense, tasty, plant-based alternative that is low in sugar.  Else is filling a much needed gap, and providing an alternative for those looking to avoid dairy or soy, and a viable option for intolerances and other diet considerations.”

Nicole Silber, RD, CSP, CLC

Else Nutrition Holdings is an advertising client of AGORA Internet Relations Corp.

Tags: , , , , ,
Posted in AGORACOM Client Feature, Else Nutrition Holdings Inc., Featured | Comments Off on CLIENT FEATURE: Else Nutrition $BABY.ca The Award Winning, Plant-Based Nutrition Company For Small Cap Investors $MAT $KMB $BMY $ABT $WYE

Eyecarrot $EYC.ca Affirms Appointment of Dr. Leonard Press as Chief Scientific Officer $EYPT $KALA

Posted by AGORACOM-JC at 7:16 AM on Thursday, May 28th, 2020
http://www.smallcapepicenter.com/eyc%20square.png
  • Announces the appointment of Dr. Leonard Press to Chief Scientific Officer
  • Dr. Press has contributed to the Company as its Director of Global Education supporting the development resources available to vision professionals through Binovi Academy and the Binovi Platform

TORONTO, ON and NEW YORK, NY / May 28, 2020 / Eyecarrot Innovations Corp (TSXV:EYC)(QTCQB:EYCCF)(FRA:2EYA:GR] announces the appointment of Dr. Leonard Press to Chief Scientific Officer. Dr. Press has contributed to the Company as its Director of Global Education supporting the development resources available to vision professionals through Binovi Academy and the Binovi Platform. Through his appointment, he will lead the Scientific Advisory Board and all scientific development efforts including the expansion of Speed of Stereopsis, established by his predecessor Dr. Selwyn Super, who passed away earlier this year.

Dr. Leonard Press is a graduate of the Pennsylvania College of Optometry, where he was a member of the Gold Key International Optometric Honor Society. He completed his Residency program in Pediatric Optometry at The Eye Institute of the Pennsylvania College of Optometry in Philadelphia, and formerly served as Chief of the Pediatric Unit of The Eye Institute. Dr. Press was recruited to the State University of New York, State College of Optometry, to serve as Chief of the Vision Therapy Service, where he was Associate Professor of Clinical Optometry for 15 years. Patients of all ages with problems related to vision development, visual processing, learning disabilities, and dyslexia are referred to Dr. Press by a wide variety of professionals through his consulting practice in Lakewood, New Jersey. He works extensively with occupational therapists, educators, and parent groups in helping parents understand the relationship between vision and learning, and opportunities for therapy to help children succeed.

“Dr. Selwyn Super was a gentleman and scholar whose foresight helped set the scientific tone for Eyecarrot and Binovi. His vision and thought processes had a significant influence on my thinking and career, as well as on the careers of many contributors to our field. I look forward to carrying on and expanding his scientific legacy as we continue to develop the Binovi suite of concepts and products.” stated Dr. Leonard Press, OD, FAAO, FCOVD

Additionally, Dr. Press has been recognized internationally for his work in the field of learning-related vision problems. He was a co-author of the Clinical Practice Guidelines in this area for the American Optometric Association and is the author of a monograph from the Optometric Extension Program on Computers and Vision Therapy Programs. He is the author of three major textbooks on vision which act as the primary reference used by therapists and doctors from around the world who are preparing for board certification in vision therapy through the College of Optometrists in Vision Development (COVD). Dr. Press served as President of the College of Optometrists in Vision Development, and formerly served on the examining board which conducts board certification. He is also a Diplomate in the Pediatric Optometry/Binocular Vision and Perception Section of the American Academy of Optometry, and the only doctor in New Jersey with specialty certification through both of these prestigious organizations.

Dr. Press served as a consultant on visual disabilities for the National Board of Medical Examiners (NBME), where he reviewed requests for test accommodations on the examinations that certifies MDs to practice Medicine in the United States. Candidates submit a request for modification of their computer monitor, extra time, or test breaks, based on supporting documentation of any visual disabilities not fully corrected by glasses or contact lenses. Many children in special education environments face similar issues in terms of Section 504 accommodations for schoolwork or standardized testing. He has lectured extensively on these subjects in the United States and abroad.

The recipient of numerous awards for his research, writing, and clinical work, Dr. Press has received the Scientific Achievement Award from the New Jersey Society in both 1995 and in 2002. He received the Skeffington Award for Excellence in Optometric Writing from the College of Optometrists in Vision Development in 1992 and was honored by his peers as Optometrist of the Year by the New Jersey Society of Optometric Physicians, previously serving as President of the organization. He was honored as the Alumnus of the Year of the Pennsylvania College of Optometry in 2003, which cited him for his outstanding contributions in the field of children’s vision and vision-related learning problems.

“Our partnership with Dr. Press has already proven to be a fruitful one for both parties, and with the unfortunate passing of Dr. Selwyn Super earlier this year, we saw it fit to invite him to take his place as a key part of the continued development of the Binovi Platform. Dr. Press’ credentials, accomplishments, and experience speak for themselves and will be a great asset to the Company moving forward. We look forward to continue working with Dr. Press as Binovi grows,” commented Adam Cegielski, President and CEO.

The Company also announces it has retained Generation IACP Inc. (“Generation“) to provide market making services with the objective of maintaining a reasonable market and improving the liquidity of its Common Shares. Under the agreement between Generation and the Company (the “Generation Agreement“), the Company has agreed to initially pay Generation a fee of C$7,500 plus applicable taxes, per month. Generation will not receive any Common Shares or options as compensation. Generation does not currently own any securities of Eyecarrot Innovations Corporation; however, Generation and its clients may acquire a direct interest in the securities of the Company. Eyecarrot Innovation Corporation and Generation are unrelated and unaffiliated entities. Generation is a member of the Investment Industry Regulatory Organization of Canada and a member firm of the Toronto Stock Exchange and the TSX Venture Exchange. The initial term of the Generation Agreement will last 6 months, and such term will be automatically renewed for subsequent 6-month periods unless terminated earlier by 30 days’ prior written notice.

About Eyecarrot Innovations Corp

Eyecarrot is a human performance technology company that has developed Binovi, a hardware and software-centered platform. Binovi combines hardware, software, specialized expert knowledge, and unique big data insights in order to deliver customized one-on-one training and treatment. Binovi is designed for vision optimization and the enhancement of skills related to human performance. We are working together under a common banner to help neuro-optometry, vision rehabilitation, and vision performance professionals gain measurable results in less time, and with less effort.

On behalf of the Board of Directors

Adam Cegielski
President | CEO

Investor Relations

Email: [email protected]
Toll-free: 1 (844) 866-6162
https://www.eyecarrot.com/investors/

Forward looking information

Certain statements contained in this news release constitute “forward-looking information” as such term is used in applicable Canadian securities laws. Forward-looking information is based on plans, expectations, and estimates of management at the date the information is provided and is subject to certain factors and assumptions, including, that the Company’s financial condition and development plans do not change as a result of unforeseen events and that the Company obtains regulatory approval. Forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause plans, estimates and actual results to vary materially from those projected in such forward-looking information. Factors that could cause the forward-looking information in this news release to change or to be inaccurate include, but are not limited to, the risk that any of the assumptions referred to prove not to be valid or reliable, that occurrences such as those referred to above are realized and result in delays, or cessation in planned work, that the Company’s financial condition and development plans change, and delays in regulatory approval, as well as the other risks and uncertainties applicable to the Company as set forth in the Company’s continuous disclosure filings filed under the Company’s profile at www.sedar.com . The Company undertakes no obligation to update these forward-looking statements, other than as required by applicable law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Tags: , ,
Posted in Eyecarrot Innovations Corp | Comments Off on Eyecarrot $EYC.ca Affirms Appointment of Dr. Leonard Press as Chief Scientific Officer $EYPT $KALA

Hollister $HOLL.ca Launches Tommy Chong’s Cannabis 1:1 Full-Spectrum Elixir $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 11:06 AM on Wednesday, May 27th, 2020
  • Announced the tincture it is manufacturing and distributing for its partner, Tommy Chong’s Cannabis, is officially ready to hit the market
  • The tincture, branded Tommy Chong’s Cannabis™ 1:1 Full Spectrum Elixir, features a sweet berry flavor and 1:1 ratio of CBD to THC; for a total of 1000mg cannabinoids (500mg CBD and 500mg THC).
  • Tommy Chong’s Cannabis™ Full Spectrum Elixir 1:1, is being distributed exclusively by Hollister Cannabis Co.’s distribution partner, Indus Holdings, Inc. (CSE: INDS)

VANCOUVER, May 27, 2020 - Hollister Biosciences Inc. (CSE: HOLL, FRANKFURT: HOB, OTC: HSTRF) (the “Company” or “Hollister“) – a diversified cannabis branding company with products in over 220 dispensaries throughout California, is pleased to announce the tincture it is manufacturing and distributing for its partner, Tommy Chong’s Cannabis, is officially ready to hit the market.

The tincture, branded Tommy Chong’s Cannabis™ 1:1 Full Spectrum Elixir, features a sweet berry flavor and 1:1 ratio of CBD to THC; for a total of 1000mg cannabinoids (500mg CBD and 500mg THC). True to the manufacturing mission of Hollister Cannabis Co., this 1:1 tincture was crafted in small, artisanal batches for optimal quality and made from premium California-grown cannabis. 

The tincture, Tommy Chong’s Cannabis™ Full Spectrum Elixir 1:1, is being distributed exclusively by Hollister Cannabis Co.’s distribution partner, Indus Holdings, Inc. (CSE: INDS)

CEO of Hollister Biosciences, Carl Saling, shared: “We are thrilled to have Tommy Chong’s Full Spectrum Elixir at Indus’ distribution center, ready to distribute to dispensaries in California. I am super proud of our team – especially through this global pandemic. We have continued to push forward and release a legendary product for a true legend!”

About Tommy Chong’s Cannabis: 

As one-half of the legendary comedy duo Cheech & Chong, Tommy Chong helped pioneer a completely unique brand of comedy directed at the counterculture movement of the early ’70s. At the heart of this brand of entertainment was cannabis. On-screen and off Tommy became a vocal advocate for his favorite herb. In a time where cannabis had to be talked about in whispers, Tommy was a loud voice for the advocacy movement, working tirelessly to destigmatize the use of this healing plant. With the legalization of recreational cannabis, Tommy’s voice continues to ring out loudly, touting its benefits and place in society. Now, Tommy is thrilled to share that passion and knowledge of cannabis with the rest of the world. Using his lifelong connections in the industry, he has made it his personal mission to share the very best product available with his fans and fellow herb connoisseurs. If anyone knows weed, it’s Tommy. And now fans of comedy and cannabis alike can experience the strains and products that Tommy himself has hand-selected.

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products.  Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.

Website: www.hollistercannabisco.com

ON BEHALF OF THE BOARD

“Carl Saling”

CEO and Director

The CSE, nor its regulation services provider, does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com

Tags: , , , , , ,
Posted in Featured, Hollister Biosciences | Comments Off on Hollister $HOLL.ca Launches Tommy Chong’s Cannabis 1:1 Full-Spectrum Elixir $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Datametrex $DM.ca Reports First Quarter Results

Posted by AGORACOM-JC at 8:42 AM on Wednesday, May 27th, 2020

Highlights for Q1 2020

  • The Company completed work for Democracy Labs on #disinformation in social media regarding #covid19 and #coronavirus and secured a relationship with Carnegie Mellon University IDeaS. These projects assisted in getting Nexalogy in front of the Government Agencies for the opportunity in the United States.
  • The Company continued the second phase of a multi-phase R&D program through the Department of National Defence’s Innovation for Defence Excellence and Security IDEaS program.  
  • The Company was chosen as preferred vendor partner by LOTTE Data Communication.

TORONTO, May 27, 2020 — Datametrex AI Limited (the “Company” or “Datametrex”) (TSXV: DM, FSE: D4G, OTC: DTMXF) is pleased to announce its financial results for Q1, ended March 31, 2020. 

Although certain projects and various sales negotiations have been postponed due to COVID-19 outbreaks, the Company was able to expand its businesses, and recorded increase in revenue for Q1 2020 by 62%, $809,402 compared to $498,565 in the previous year. Operating costs were reduced by 31% to $1,162,723 compared to $1,692,958 in the previous year. The net results  improved significantly with a decrease by 25%, ($721,761) compared to ($904,792) in the previous year. The Adjusted EBITDA also had a significant improvement with a decrease by 177%, ($257,303) compared to ($712,256). 

“In Q1 2020, we achieved multiple key milestones and made significant strides in strengthening our AI platform and offering, reducing operating costs, increasing sales, and focusing on our core business. This resulted in a substantial improvement to the bottom line,” says Marshall Gunter, CEO of the Company.

Highlights for Q1 2020

  • The Company completed work for Democracy Labs on #disinformation in social media regarding #covid19 and #coronavirus and secured a relationship with Carnegie Mellon University IDeaS. These projects assisted in getting Nexalogy in front of the Government Agencies for the opportunity in the United States.
  • The Company continued the second phase of a multi-phase R&D program through the Department of National Defence’s Innovation for Defence Excellence and Security IDEaS program.  
  • The Company was chosen as preferred vendor partner by LOTTE Data Communication.

Financial Highlights

The following table summarizes revenue, net loss and EBITDA* and Adjusted EBITDA* for the three months ended March 31, 2020 and 2019.

 For the three months ended 
 March 31, 2020 March 31, 2019 %
 $ $  
REVENUE  809,402   498,565 62%
NET LOSS  (721,761)  (904,792)25%
EBITDA  (528,303)  (723,529)37%
EBITDA per share  (0.002)  (0.003)68%
Adjusted EBTDA  (257,303)  (712,256)177%
Adjusted EBITDA per share  (0.001)  (0.003)34%

* Note: EBITDA (non-IFRS measures) is calculated as Net Loss ($721,761) adjusted for 1. Income taxes of ($16,207), 2. Depreciation and amortization of $194,899, and 3. Interest and accretion of $14,766. Adjusted EBITDA (non-IFRS measures) is calculated as EBITFA adjusted for share based compensation of 271,000.

Non-IFRS financial measures do not have standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Specific items may only be relevant in certain periods. For reconciliation of non-IFRS financial measures please refer to the Company’s Management Discussion and Analysis for the three months ended March 31, 2020.

The financial statements, notes to the financial statements and Management’s Discussion and Analysis for the three months ended March 31, 2020 are available on the Company’s profile at SEDAR at www.sedar.com.

About Datametrex

Datametrex AI Limited is a technology focused company with exposure to Artificial Intelligence and Machine Learning through its wholly owned subsidiary, Nexalogy (www.nexalogy.com).

For further information, please contact:

Marshall Gunter – CEO
Phone: (514) 295-2300
Email: [email protected]

Jeff Stevens- Advisor
Phone: (647) 400-8494
Email: [email protected]

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws.  All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

Tags: , , , ,
Posted in Datametrex AI Limited | Comments Off on Datametrex $DM.ca Reports First Quarter Results

Empower $CBDT.ca Expands Its Online Education with the Support of EuroLife $EURO.ca to Promote the Benefits of Functional Mushrooms and Psilocybin to Positively Impact Health and Wellness $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 7:00 AM on Wednesday, May 27th, 2020

– Company is forming a global mushroom education initiative with EuroLife Brands that will leverage the cannvas.me platform

– new initiative expands the original agreement by formalizing a cloud-based, globally accessible, leading educational experience for patients, clinics, and academic circles to participate, learn, interact, and create information on the uses, treatments, and applications of mushrooms for health and wellness.

VANCOUVER, BC / May 27th, 2020 / EMPOWER CLINICS INC. (CSE:CBDT) (OTCQB:EPWCF) (Frankfurt 8EC) (“Empower” or the “Company“), a vertically integrated life sciences company, is pleased to announce that further to the definitive agreement announced on May 15th, 2020 the Company is forming a global mushroom education initiative with EuroLife Brands (“EuroLife”) that will leverage the cannvas.me platform.

The new initiative expands the original agreement by formalizing a cloud-based, globally accessible, leading educational experience for patients, clinics, and academic circles to participate, learn, interact, and create information on the uses, treatments, and applications of mushrooms for health and wellness. The global initiative will be positioned as an educational platform but will also accept clinical trial results, integrate with universities and academic circles, provide knowledge and a safe learning experience free from the outside influence of misinformation.

“Our global mushroom education initiative will provide significantly more information pertaining to the treatment of a number of ailments using plant-based treatment options,” said Steven McAuley, chairman and chief executive officer of Empower. “We are proud to bring premium health and wellness products to our patients online and in our clinics and mushrooms are already a part of our expanding product line in this category. We look forward to working with the team at EuroLife to launch this initiative in the very near future.”

“We have an opportunity to be one of the first online education platforms to deliver information on the benefits of using mushrooms for nutrition and health and wellness,” said Shawn Moniz, Chief Executive Officer, EuroLife Brands Inc. “Our Cannvas.me education portal is scalable and provides quick and easy access to Empower employees, medical professionals and retail consumers who are in need of this important information. We will continue to leverage our technology to move EuroLife forward.”

A report produced by Research and Markets estimates the global mushroom market was over US$38 billion in 2017 and forecasted to expand at a CAGR of 7.9 per cent from 2018 to 2026. Increasing consumer awareness regarding the health benefits offered by mushrooms is a key factor influencing the growth of the mushroom market at present. Consumer mushroom consumption in supermarkets, restaurants, hotels, and cafeterias are also expected to add to the market demand. Mushrooms are considered a super food as they contain protein, vitamins, minerals and antioxidants, with a great deal of nutritional value and micronutrients. They are low in carbohydrates, high in fiber, and a good source of B-vitamins (riboflavin, pantothenic acid, and niacin), iron, and selenium.

EuroLife and Empower will create a mushroom portal which will leverage the same technology platform used for EuroLife’s cannabis portal and will include educational modules on a wide range of topics. The platform will also incorporate dynamic and interactive elements to facilitate learning.

ABOUT EMPOWER

Empower is a vertically integrated health & wellness company with a network of corporate and franchised health & wellness clinics in the U.S. The Company is a leading multi-state operator of a network of physician-staffed wellness clinics, focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has launched Dosed Wellness Ltd. to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options.

About EuroLife Brands Inc.

EuroLife Brands is a vertically integrated enterprise focused on the pan-European health and wellness sector.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Steven McAuley

Chairman & CEO

[email protected]

604-789-2146

Investors: Dustin Klein

SVP, Business Development

[email protected]

720-352-1398

For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARI

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws.All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding: the Company’s expected timing of filing of its Annual Filings, the Company’s intention to create psilocybin and psychedelics divisions, that market research on advancements in psilocybin and psychedelics in North America and globally will create greater shareholder value, the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower’s patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond; the ability of the Company to complete or execute phases One, Two, Three or Four of COVID-19 test programs, and Psychedelic substances remain illegal in most countries, so please reference your local laws in relation to medical or recreational use. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.I

Tags: , , , , ,
Posted in Empower Clinics Inc. | Comments Off on Empower $CBDT.ca Expands Its Online Education with the Support of EuroLife $EURO.ca to Promote the Benefits of Functional Mushrooms and Psilocybin to Positively Impact Health and Wellness $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

PyroGenesis $PYR.ca Increases Stake in HPQ Silicon $HPQ.ca $FSLR $SPWR $CSIQ $XMG.ca

Posted by AGORACOM-JC at 11:07 AM on Tuesday, May 26th, 2020

– Directors of the Corporation have agreed to settle an outstanding debt for services rendered by PyroGenesis Canada Inc, (TSX-V: PYR) in connection with works relating to leasehold improvements done in the dedicated PUREVAPTM Quartz Reduction Reactor (“QRR”) premises within PyroGenesis production plant.

MONTREAL, May 26, 2020 — HPQ Silicon Resources Inc.  (“HPQ” or the “Company”) TSX-V: HPQ; FWB: UGE; Other OTC : URAGF; would like inform shareholders that the Directors of the Corporation have agreed to settle an outstanding debt for services rendered by PyroGenesis Canada Inc, (TSX-V: PYR) in connection with works relating to leasehold improvements done in the dedicated PUREVAPTM Quartz Reduction Reactor (“QRR”) premises within PyroGenesis production plant.

The outstanding debt of $395,514, will be settled by issuing 4,394,600 Units at a price of $0.09 per unit. Each unit is comprised of one common share and one common share purchase warrant.  Each warrant will allow its holder to subscribe to one common share at the price of $0.10 for a period of 36 months from the date of closing.  Each share issued pursuant to the debt settlement will have a mandatory four (4) month and one (1) day holding period from the date of closing.  This settlement is subject to the approval of the TSX Venture Exchange.

“This transaction is a demonstration of the strong cooperation HPQ and PyroGenesis are implementing as we develop both the PUREVAPTM Quartz Reduction Reactor (QRR) and the PUREVAPTM Silicon Nano Reactor (SiNR) processes,” said Bernard Tourillon, President & CEO of HPQ Silicon.  “Our PUREVAPTM processes opens up unique multibillion-dollar business opportunity for HPQ and PyroGenesis, as we strive to deliver the critical Silicon nano- materials required by the surging Li-ion battery market.”

About Silicon

Silicon (Si), also known as silicon metal, is one of today’s strategic materials needed to fulfil the Renewable Energy Revolution (“RER”) presently under way. Silicon does not exist in its pure state; it must be extracted from quartz (SiO2), in what has historically been a capital and energy intensive process.

About HPQ Silicon

HPQ Silicon Resources Inc. (TSX-V: HPQ) is a producer of Silicon Innovation that is building a portfolio of unique high value silicon products needed for the RER.

Working with PyroGenesis Canada Inc. (TSX-V: PYR), a high-tech company that designs, develops, manufactures and commercializes plasma – based processes, HPQ is developing:

  • The PUREVAPTM “Quartz Reduction Reactors” (QRR), an innovative process (patent pending), which will permit the one step transformation of quartz (SiO2) into high purity silicon (Si) at reduced costs, energy input, and carbon footprint that will propagate its considerable renewable energy potential;
    • HPQ is in the process of becoming the lowest cost (Capex and Opex) producer of silicon (Si) and high purity silicon (3N – 4N Si);
  • The PUREVAPTM Silicon Nano Reactor (SiNR), a new proprietary process that can use different purities of silicon (Si) as feedstock, to make spherical silicon nanopowders and nanowires;
    • HPQ objective is to become the lowest cost manufacturer of spherical Si nanopowders and silicon-based composites needed by manufacturers of next-generation lithium-ion batteries;
    • During the coming months, spherical Si nanopowders and nanowires silicon-based composite samples requested by industry participants and research institutions’ will be produced using the newly develop PUREVAPTM SiNR process.

HPQ is also working with industry leader Apollon Solar of France to:

  • Use their patented process and develop a capability to produce commercially porous silicon (Si) wafers and porous silicon (Si) powders;
    • The collaboration will allow HPQ to become the lowest cost producer of porous silicon wafers for all-solid -state batteries and porous silicon powders for Li-ion batteries.
    • The plan is to deliver porous Si wafer to a battery manufacturer (under NDA) for testing in 2020.

This News Release is available on the company’s CEO Verified Discussion Forum, a moderated social media platform that enables civilized discussion and Q&A between Management and Shareholders. 

Disclaimers:

This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or the securities laws of any state of the United States and may not be offered or sold within the United States or to, or for the account or the benefit of, U.S. persons (as defined in Regulation S under the U.S.  Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from such registration requirements.

The Corporation’s interest in developing the PUREVAP™ QRR and any projected capital or operating cost savings associated with its development should not be construed as being related to the establishing the economic viability or technical feasibility of any of the Company’s Quartz Projects.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Company’s current expectation and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Company’s on-going filings with the security’s regulatory authorities, which filings can be found at www.sedar.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information contact

Bernard J. Tourillon, Chairman, President and CEO Tel (514) 907-1011
Patrick Levasseur, Vice-President and COO Tel: (514) 262-9239
http://www.hpqsilicon.com Email: [email protected] 

Tags: , , , ,
Posted in PyroGenesis Canada Inc. | Comments Off on PyroGenesis $PYR.ca Increases Stake in HPQ Silicon $HPQ.ca $FSLR $SPWR $CSIQ $XMG.ca

Spyder Cannabis $SPDR.ca Announces Corporate Update $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 8:17 AM on Tuesday, May 26th, 2020
  • Company is now awaiting receipt of its RSA (“Retail Store Authorization”) for its Niagara Falls dispensary located at 6474 Lundy’s Lane
  • Company is awaiting a final inspection of its dispensary scheduled for the beginning of June, at which point, it intends to begin operations at its Calgary dispensary, located at 104-58th Ave, SE, suite 140
  • In order to address the challenges presented by the COVID 19 crisis, the company has focus on building up the online and e-commerce components for its US Hemp CBD only locations, in Atlantic City and West Palm Beach.

Vaughan, Ontario–(May 26, 2020) – Spyder Cannabis Inc. (TSXV: SPDR) (“Spyder” or the “Company”) and its wholly-owned associated applicants, The Green Spyder Inc. and Spyder Cannabis Subco Inc., is pleased to provide the following update:

Niagara Falls Cannabis Dispensary

Further to the announcement of receipt of its ROL (“Retail Operator License”), the company is now awaiting receipt of its RSA (“Retail Store Authorization”) for its Niagara Falls dispensary located at 6474 Lundy’s Lane. The company plans to begin operations at the location as soon as the RSA is issued and final inspection is completed, while ensuring it complies with COVID-19 provincial regulations and focusing on its curbside pickup and delivery business.

Calgary Cannabis Dispensary

Further to the announcement of receipt of its Conditional Cannabis License, the company is awaiting a final inspection of its dispensary scheduled for the beginning of June, at which point, it intends to begin operations at its Calgary dispensary, located at 104-58th Ave, SE, suite 140.

Online and e-Commerce

In order to address the challenges presented by the COVID 19 crisis, the company has focus on building up the online and e-commerce components for its US Hemp CBD only locations, in Atlantic City and West Palm Beach. Specifically, the company has launched a US website as well as an affiliate program to generate increased awareness of the Spyder brand at ShopSPDR.com.

Filing Extension of Annual Disclosure Documents Due to COVID-19

Due to circumstances created by the COVID – 19 pandemic Spyder will not be filing its audited financial statements and related management discussion and analysis for the fiscal year ended January 31, 2020 by the scheduled due date of June 1, 2020, as required under section 4.4(b) and section 5.1(1) of National Instrument 51-102 – Continuous Disclosure Obligations (“NI 51-102”).

As required by Ontario Instrument 51-502 Temporary Exemption from Certain Corporate Finance Requirements (OSC Instrument 51-502), BC Instrument 51-515 Temporary Exemption from Certain Corporate Finance Requirements (BC Instrument 51-515), Blanket Order 51-517 Temporary Exemption from Certain Corporate Finance Requirements (ASC Blanket Order 51-517) and Manitoba Blanket Order 52-502 Temporary Exemption from Certain Corporate Finance Requirements (Manitoba Blanket Order 52-502), the Company discloses the following:

• The Company’s management and other insiders will be subject to a trading black-out that reflects the principles in Section 9 of National Policy 11-207 – Failure-to-File Cease Trade Orders until its audited financial statements and related management discussion and analysis for the fiscal year ended January 31, 2020;

• The Company expects to file its audited financial statements and related management discussion and analysis for the fiscal year ended January 31, 2020 on or about July 15, 2020

About Spyder Cannabis Inc.

Spyder is a Cannabis, Vape and CBD retailer that operates in jurisdictions where the products are federally legal in both Canada and the United States. The Company, through its subsidiaries, is a retailer involved in the development of three retail business units. The first is the sale of Cannabis products, the second is the sale of Hemp CBD in the United States only, the third is the sale of smoking cessation products in Ontario.

Cautionary Statements

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release includes statements containing certain ‘forward-looking information” within the meaning of applicable securities laws (‘forward-looking statements”). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur.

For more information, please contact:

Spyder Cannabis Inc.

Dan Pelchovitz
President & Chief Executive Officer
Telephone: 1.888.504.7737
Email: [email protected]

Tags: , , , ,
Posted in Spyder Cannabis Inc. | Comments Off on Spyder Cannabis $SPDR.ca Announces Corporate Update $CGC $ACB $APH $CRON.ca $OGI.ca

Eurolife Brands $EURO.ca and Empower Clinics $CBDT.ca Form Global Mushroom Education Initiative $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 6:59 AM on Tuesday, May 26th, 2020
  • New initiative expands the original agreement by formalizing a cloud-based, globally accessible, leading educational experience for patients, clinics, and academic circles to participate, learn, interact, and create information on the uses, treatments, and applications of mushrooms for health and wellness
  • Will be positioned as an educational platform but will also accept clinical trial results, integrate with universities and academic circles, provide knowledge and a safe learning experience free from the outside influence of mis-information

Toronto, Ontario–(May 26, 2020) –  EuroLife Brands (CSE: EURO) (FSE: 3CMA) (OTC PINK: EURPF) (“EuroLife” or the “Company”), a vertically integrated enterprise focused on the pan-European health and wellness sector, is pleased to announce that further to the definitive agreement announced on May 15th, 2020 the Company is forming a global mushroom education initiative with Empower Clinics Inc. (CSE: CBDT) (OTCQB: EPWCF) (FSE: 8EC) (“Empower“), a vertically integrated and growth-oriented life sciences company.

The new initiative expands the original agreement by formalizing a cloud-based, globally accessible, leading educational experience for patients, clinics, and academic circles to participate, learn, interact, and create information on the uses, treatments, and applications of mushrooms for health and wellness. The global initiative will be positioned as an educational platform but will also accept clinical trial results, integrate with universities and academic circles, provide knowledge and a safe learning experience free from the outside influence of mis-information.

“Our global mushroom education initiative will provide significantly more information pertaining to the treatment of a number of ailments using these alternative plant-based treatment options,” said Steven McAuley, chairman and chief executive officer of Empower. “We are proud to bring premium health and wellness products to our patients online and in our clinics and mushrooms are already a part of our expanding product line in this category. We look forward to working with the team at EuroLife to launch this initiative in the very near future.”

“We have an opportunity to be one of the first online education platforms to deliver information on the benefits of using mushrooms for nutrition and health and wellness,” said Shawn Moniz, Chief Executive Officer, EuroLife Brands Inc. “Our Cannvas.me education portal is scalable and provides quick and easy access to Empower employees, medical professionals and retail consumers who are in need of this important information. We will continue to leverage our technology to move EuroLife forward.”

A report produced by Research and Markets estimates the global mushroom market was over US$38 billion in 2017 and forecasted to expand at a CAGR of 7.9 per cent from 2018 to 2026. Increasing consumer awareness regarding the health benefits offered by mushrooms is a key factor influencing the growth of the mushroom market at present. Consumer mushroom consumption in supermarkets, restaurants, hotels, and cafeterias are also expected to add to the market demand. Mushrooms are considered a super food as they contain protein, vitamins, minerals and antioxidants, with a great deal of nutritional value and micronutrients. They are low in carbohydrates, high in fiber, and a good source of B-vitamins (riboflavin, pantothenic acid, and niacin), iron, and selenium. 

EuroLife and Empower will create a mushroom portal which will leverage the same technology platform used for EuroLife’s cannabis portal and will include educational modules on a wide range of topics. The platform will also incorporate dynamic and interactive elements to facilitate learning.

About Empower Clinics Inc.

Empower is a vertically integrated health & wellness brand with a network of corporate and franchised health & wellness clinics in the U.S. The Company is building its first hemp-derived CBD extraction facility and produces its proprietary line of cannabidiol (CBD) based products. The Company is a leading multi-state operator of a network of physician-staffed wellness clinics, focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has launched Dosed Wellness Ltd. to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options.

About EuroLife Brands Inc.

EuroLife Brands (CSE: EURO) (FSE: 3CMA) (OTCPK: EURPF) is a vertically integrated enterprise focused on the pan-European health and wellness sector.

For additional information:

Contact: [email protected] or visit EuroLifeBrands.com

No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.

Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer‘s future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company‘s Management‘s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.

Tags: , , , , , ,
Posted in All Recent Posts, Empower Clinics Inc. | Comments Off on Eurolife Brands $EURO.ca and Empower Clinics $CBDT.ca Form Global Mushroom Education Initiative $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

« Older Entries
Newer Entries »